Recursion Pharmaceuticals Inc. Class A (RXRX)
$3.05
$-0.10
(-3.17%)
As on 13-May-2026 16:29EDT
Market cap
$1,730 Mln
Revenue (TTM)
$66 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
524,677,865
5 Years Aggregate
CFO
$-632.36 Mln
EBITDA
$-864.46 Mln
Net Profit
$-895.97 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Recursion Pharmaceuticals Inc. Class A (RXRX)
| -25.4 | -7.0 | -14.8 | -29.6 | -16.8 | -32.8 | -- |
|
BSE Sensex*
| -11.5 | -2.5 | -9.3 | -7.6 | 6.5 | 9.0 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Recursion Pharmaceuticals Inc. Class A (RXRX)
| -39.5 | -31.2 | 27.9 | -55.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Recursion Pharmaceuticals Inc. Class A (RXRX)
|
3.1 | 1,730.3 | 66.3 | -559.8 | -890.0 | -54 | -- | 1.7 |
| 77.9 | 10,950.2 | 622.0 | -300.9 | -7.4 | -62.9 | -- | 16.7 | |
| 77.2 | 10,123.1 | 105.8 | -829.6 | -718.2 | -- | -- | 60.3 | |
| 51.3 | 12,494.9 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.5 | 6.3 | |
| 98.4 | 12,823.7 | 1,080.2 | -433.2 | -29.6 | -- | -- | 55.7 | |
| 8.2 | 8,494.0 | 141.0 | -854.5 | -97.9 | -- | -- | 0.0 | |
| 312.6 | 9,223.6 | 417.3 | 225.0 | 42.8 | 18.6 | 41.8 | 7.1 | |
| 518.9 | 11,459.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.6 | |
| 423.8 | 11,917.7 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.2 | 20.2 | |
| 346.8 | 9,250.5 | 0.0 | -326.5 | -- | -37.2 | -- | 6.5 |
Shareholding Pattern
View DetailsAbout Recursion Pharmaceuticals Inc. Class A (RXRX)
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug... discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Address: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101 Read more
-
Co-Founder, CEO & Director
Dr. Christopher C. Gibson Ph.D.
-
Co-Founder, CEO & Director
Dr. Christopher C. Gibson Ph.D.
-
Headquarters
Salt Lake City, UT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Recursion Pharmaceuticals Inc. Class A (RXRX)
What is the current share price of Recursion Pharmaceuticals Inc Class A (RXRX) Today?
The share price of Recursion Pharmaceuticals Inc Class A (RXRX) is $3.05 (NASDAQ) as of 13-May-2026 16:29 EDT. Recursion Pharmaceuticals Inc Class A (RXRX) has given a return of -16.77% in the last 3 years.
What is the current PB & PE ratio of Recursion Pharmaceuticals Inc Class A (RXRX)?
Since, TTM earnings of Recursion Pharmaceuticals Inc Class A (RXRX) is negative, P/E ratio is not available.
The P/B ratio of Recursion Pharmaceuticals Inc Class A (RXRX) is 1.72 times as on 12-May-2026, a 62 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.84
|
1.62
|
|
2024
|
-3.99
|
1.79
|
|
2023
|
-6.25
|
4.43
|
|
2022
|
-5.67
|
2.79
|
|
2021
|
-16.26
|
5.33
|
What is the 52 Week High and Low of Recursion Pharmaceuticals Inc Class A (RXRX)?
The 52-week high and low of Recursion Pharmaceuticals Inc Class A (RXRX) are Rs 7.18 and Rs 2.80 as of 14-May-2026.
What is the market cap of Recursion Pharmaceuticals Inc Class A (RXRX)?
Recursion Pharmaceuticals Inc Class A (RXRX) has a market capitalisation of $ 1,730 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Recursion Pharmaceuticals Inc Class A (RXRX)?
Before investing in Recursion Pharmaceuticals Inc Class A (RXRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.